Fibrocell Science (NASDAQ:FCSC) has been given a $6.00 price target by stock analysts at HC Wainwright in a research note issued on Monday. The brokerage currently has a “buy” rating on the stock.
Separately, Zacks Investment Research raised shares of Fibrocell Science from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research report on Tuesday, March 13th.
Shares of Fibrocell Science stock opened at $0.66 on Monday. Fibrocell Science has a 1 year low of $0.51 and a 1 year high of $4.64. The firm has a market cap of $17.61, a P/E ratio of -0.36 and a beta of 0.51.
Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings results on Monday, March 19th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.42). research analysts anticipate that Fibrocell Science will post -1.63 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Third Security LLC lifted its stake in Fibrocell Science by 49.2% during the fourth quarter. Third Security LLC now owns 8,267,413 shares of the company’s stock worth $5,292,000 after purchasing an additional 2,727,273 shares during the last quarter. Sabby Management LLC bought a new position in Fibrocell Science during the fourth quarter worth $733,000. Armistice Capital LLC bought a new position in Fibrocell Science during the fourth quarter worth $393,000. Anson Funds Management LP bought a new position in Fibrocell Science during the fourth quarter worth $287,000. Finally, Pura Vida Investments LLC bought a new position in Fibrocell Science during the third quarter worth $909,000. Hedge funds and other institutional investors own 48.64% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Fibrocell Science (FCSC) Given a $6.00 Price Target by HC Wainwright Analysts” was first posted by Stock Observer and is the property of of Stock Observer. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.thestockobserver.com/2018/03/21/fibrocell-science-fcsc-given-a-6-00-price-target-by-hc-wainwright-analysts.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.